JP7316946B2 - 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 - Google Patents

内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 Download PDF

Info

Publication number
JP7316946B2
JP7316946B2 JP2019572539A JP2019572539A JP7316946B2 JP 7316946 B2 JP7316946 B2 JP 7316946B2 JP 2019572539 A JP2019572539 A JP 2019572539A JP 2019572539 A JP2019572539 A JP 2019572539A JP 7316946 B2 JP7316946 B2 JP 7316946B2
Authority
JP
Japan
Prior art keywords
fgf21
klotho
construct
polypeptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019572539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526503A (ja
JP2020526503A5 (https=
Inventor
ジョセフ シュレジンジャー
サンウォン リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2020526503A publication Critical patent/JP2020526503A/ja
Publication of JP2020526503A5 publication Critical patent/JP2020526503A5/ja
Priority to JP2023083756A priority Critical patent/JP2023103455A/ja
Application granted granted Critical
Publication of JP7316946B2 publication Critical patent/JP7316946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
JP2019572539A 2017-07-06 2018-07-05 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 Active JP7316946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023083756A JP2023103455A (ja) 2017-07-06 2023-05-22 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529215P 2017-07-06 2017-07-06
US62/529,215 2017-07-06
PCT/US2018/040932 WO2019010314A1 (en) 2017-07-06 2018-07-05 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ENDOCRINE FGF-RELATED DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023083756A Division JP2023103455A (ja) 2017-07-06 2023-05-22 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020526503A JP2020526503A (ja) 2020-08-31
JP2020526503A5 JP2020526503A5 (https=) 2021-08-12
JP7316946B2 true JP7316946B2 (ja) 2023-07-28

Family

ID=64950347

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019572539A Active JP7316946B2 (ja) 2017-07-06 2018-07-05 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法
JP2023083756A Pending JP2023103455A (ja) 2017-07-06 2023-05-22 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023083756A Pending JP2023103455A (ja) 2017-07-06 2023-05-22 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法

Country Status (7)

Country Link
US (2) US11365228B2 (https=)
EP (1) EP3649157A4 (https=)
JP (2) JP7316946B2 (https=)
CN (1) CN110997726B (https=)
AU (1) AU2018297285A1 (https=)
CA (1) CA3069143A1 (https=)
WO (1) WO2019010314A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用
WO2021231720A1 (en) * 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN113735959B (zh) * 2021-03-12 2023-07-04 江南大学 一种治疗nash的fgf类似物
CN113105561B (zh) * 2021-04-30 2021-12-03 江南大学 一种双靶点融合蛋白的制备方法和应用
WO2025059130A1 (en) * 2023-09-11 2025-03-20 Yale University Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof
CN118852466B (zh) * 2024-08-08 2025-03-28 郑州大学第三附属医院(河南省妇幼保健院) Klotho修饰的CAR-T结构及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523561A (ja) 2008-06-04 2011-08-18 アムジエン・インコーポレーテツド Ｆｇｆ２１突然変異体及びその使用
JP2013512689A (ja) 2009-12-07 2013-04-18 アムジエン・インコーポレーテツド β‐クロトー、ＦＧＦ受容体、およびその複合体と結合するヒト抗原結合タンパク質
US20130231277A1 (en) 2012-03-02 2013-09-05 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
US20130331316A1 (en) 2012-06-07 2013-12-12 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
JP2014527402A (ja) 2011-07-01 2014-10-16 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害及び疾患の治療のための組成物、使用及び方法
JP2017509628A (ja) 2014-03-11 2017-04-06 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
SI2550972T1 (en) 2007-04-02 2018-05-31 Genentech, Inc. A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
JP5927782B2 (ja) 2010-06-15 2016-06-01 国立大学法人広島大学 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途
MX2013013044A (es) 2011-05-10 2014-02-20 Amgen Inc METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO.
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9400677B2 (en) 2013-01-02 2016-07-26 Apple Inc. Adaptive handling of priority inversions using transactions
AU2015237176A1 (en) 2014-03-28 2016-10-20 New York University FGF23 fusion proteins
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
WO2016204884A1 (en) 2015-06-18 2016-12-22 Albert Einstein College Of Medicine, Inc. Fgf receptor ligands for treating diabetes and obesity
WO2017180988A2 (en) * 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
CA3026510A1 (en) 2016-05-25 2017-11-30 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of secretory disorders
WO2018026899A1 (en) 2016-08-03 2018-02-08 Joslin Diabetes Center, Inc. Methods and compositions for treating hypoglycemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523561A (ja) 2008-06-04 2011-08-18 アムジエン・インコーポレーテツド Ｆｇｆ２１突然変異体及びその使用
JP2013512689A (ja) 2009-12-07 2013-04-18 アムジエン・インコーポレーテツド β‐クロトー、ＦＧＦ受容体、およびその複合体と結合するヒト抗原結合タンパク質
JP2014527402A (ja) 2011-07-01 2014-10-16 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害及び疾患の治療のための組成物、使用及び方法
US20130231277A1 (en) 2012-03-02 2013-09-05 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
US20130331316A1 (en) 2012-06-07 2013-12-12 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
JP2017509628A (ja) 2014-03-11 2017-04-06 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ganesh Kolumam et al.，EBioMedicine，2015年05月30日，Vol. 2，p. 730-743
Regina Goetz et al.，Molecular and Cellular Biology，2012年05月，Vol. 32, No. 10，p. 1944-1954
Richard Smith et al.，PLOS ONE，2013年04月，Vol. 8, Issue 4, e61432，p. 1-11
Zoller, M J, and M Smith，Nucleic Acids Research，Vol. 10, No. 20，1982年，p. 6487-6500

Also Published As

Publication number Publication date
EP3649157A1 (en) 2020-05-13
JP2023103455A (ja) 2023-07-26
JP2020526503A (ja) 2020-08-31
US20240083961A1 (en) 2024-03-14
EP3649157A4 (en) 2021-07-28
CA3069143A1 (en) 2019-01-10
CN110997726B (zh) 2024-10-29
US11365228B2 (en) 2022-06-21
CN110997726A (zh) 2020-04-10
US12534503B2 (en) 2026-01-27
AU2018297285A1 (en) 2020-01-30
WO2019010314A1 (en) 2019-01-10
US20200131257A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7316946B2 (ja) 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法
TWI476003B (zh) 能夠特異性結合tfpi之k2域的單株抗體、表現其的真核細胞、包含其的醫藥組成物、及其醫藥用途
JP2019510739A (ja) Ｇｆｒａｌ受容体療法
EP3083683B1 (en) Compositions and methods for treating fatty tissue buildup
TW201006492A (en) FGF-R4 receptor-specific antagonists
BR112015005466B1 (pt) Polipeptídeo e seu uso, composição farmacêutica e seu uso, molécula de ácido nucleico isolada, célula hospedeira, e método de detecção ou medição da miostatina em uma amostra
JP2021529796A (ja) 多特異性Ｗｎｔ代替分子及びその使用
JP2019521647A (ja) 成長分化因子１５に対する抗体およびそれらの使用
BR112016008125B1 (pt) Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
TW200829270A (en) Agonist TrkB antibodies and uses thereof
TW202317175A (zh) 用於重量管理及相關代謝病症之療法
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
BR112019015479A2 (pt) Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
WO2008128455A1 (en) Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof
CN113637070A (zh) 抗spike蛋白的抗体或抗原结合片段及其应用
JP6890340B2 (ja) グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法
JP2021500895A (ja) Ａｌｋ７結合タンパク質およびその使用
BR112019016065A2 (pt) Inibição da agregação de plaquetas usando anticorpos anti-humanos de gpvi
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
JP2025504036A (ja) 親和性が増強された抗ｅｃｍナノボディ－サイトカイン融合体およびその応用
JP6480479B2 (ja) Ｇｉｓｔの治療法
TW200838559A (en) Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
WO2021197340A1 (zh) 用于治疗冠状病毒的抗体、融合蛋白及其应用
CN113637083A (zh) 用于治疗冠状病毒的融合蛋白及其应用
US9260486B2 (en) Peptidic activators of type I cGMP dependent protein kinases and uses thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210702

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230622

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230718

R150 Certificate of patent or registration of utility model

Ref document number: 7316946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150